Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q10471

UPID:
GALT2_HUMAN

ALTERNATIVE NAMES:
Polypeptide GalNAc transferase 2; Protein-UDP acetylgalactosaminyltransferase 2; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 2

ALTERNATIVE UPACC:
Q10471; A8K1Y3; B7Z8V8; C5HU00; Q9NPY4

BACKGROUND:
Polypeptide N-acetylgalactosaminyltransferase 2 is essential for the biosynthesis of glycoproteins, impacting various physiological functions through its role in the glycosylation of proteins like IgA1, APOC-III, and ANGPTL3. Its broad substrate specificity underlines its significance in cellular processes.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Polypeptide N-acetylgalactosaminyltransferase 2 could open doors to potential therapeutic strategies for diseases linked to glycosylation defects, including Congenital disorder of glycosylation 2T. Exploring its function further may reveal new pathways for intervention in these complex disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.